Indicações Clínicas Atuais para Enteroscopia por Cápsula

Bruno ROSA1, José COTTER2,3

ABSTRACT
Introduction: Small bowel capsule endoscopy is currently the first line diagnostic examination for many diseases affecting the small bowel. This article aims to review and critically address the current indications of small bowel capsule endoscopy in clinical practice.

Material and Methods: Bibliographic review of relevant and recent papers indexed in PubMed.

Results and Discussion: Small bowel capsule endoscopy enables a non-invasive full-assessment of the small bowel mucosa, with high diagnostic yield even for subtle lesions. In patients with obscure gastrointestinal bleeding, diagnostic yield is higher when performed early after the onset of bleeding. Endoscopic treatment of angiectasias using balloon-assisted enteroscopy may contribute to reduce rebleeding, while the risk of rebleeding in patients with “negative” small bowel capsule endoscopy is debatable. Cross-sectional imaging may be more accurate than small bowel capsule endoscopy for the diagnosis of large small bowel tumors. The Smooth Protruding Index on Capsule Endoscopy (SPICE score) may help to differentiate submucosal tumors from innocent bulges. Small bowel capsule endoscopy is also a key diagnostic instrument in patients with suspected Crohn’s disease and non-diagnostic ileocolonoscopy; it may also influence prognosis and therapeutic management, by determining disease extent and activity in patients with known Crohn’s disease. The role of small bowel capsule endoscopy to investigate possible complications in patients with non-responsive coeliac disease is evolving.

Conclusions: Small bowel capsule endoscopy is a valuable diagnostic instrument for patients with obscure gastrointestinal bleeding and/or suspected small bowel tumors; it may also be a key examination in patients with suspected Crohn’s disease, or patients with known Crohn’s disease to fully assess disease extension and activity; finally, it may contribute for the diagnosis of complications of non-responsive coeliac disease.

Keywords: Capsule Endoscopy; Intestinal Diseases.

RESUMO
Introdução: A enteroscopia por cápsula é o exame de primeira linha no diagnóstico de diversas patologias do intestino delgado. Este artigo tem por objectivo rever e analisar criticamente as indicações actuais para enteroscopia por cápsula na prática clínica.

Material e Métodos: Revisão bibliográfica suportada em artigos indexados na PubMed.

Resultados e Discussão: A enteroscopia por cápsula permite a avaliação não invasiva da mucosa do intestino delgado, com elevado rendimento diagnóstico. Em doentes com hemorragia digestiva de causa obscura, o rendimento da enteroscopia por cápsula aumenta quando realizada precocemente após o evento hemorrágico. O tratamento das angiectasias com enteroscopia assistida por balão permite diminuir a recidiva hemorrágica, enquanto o risco de recidiva em doentes com enteroscopia por cápsula “negativa” é controvertido. A enteroscopia por cápsula pode superiorizar-se à enteroscopia por cápsula no diagnóstico de alguns tumores. O ‘Smooth Protruding Index on Capsule Endoscopy’ (score SPICE) auxilia na diferenciação entre verdadeiros tumores submucosos e abaulamentos não patológicos. A enteroscopia por cápsula é valiosa em doentes com suspeita de doença de Crohn quando a ileocolonoscopia não é diagnóstica, permitindo também estudar a extensão e actividade das lesões em doentes com diagnóstico prévio de doença de Crohn, com potenciais implicações prognósticas e terapêuticas. A enteroscopia por cápsula permite ainda o diagnóstico de complicações em doentes com doença celíaca refratária.

Conclusões: Actualmente, a importância da enteroscopia por cápsula é reconhecida no contexto da hemorragia digestiva de causa obscura e/o suspeita de tumores do intestino delgado, bem como na suspeita de doença de Crohn ou em doentes com doença de Crohn conhecida para determinar a localização, extensão e actividade da doença, e ainda para a investigação de doentes com doença celíaca refratária.

Palavras-chave: Doenças Intestinais; Enteroscopia por Cápsula.

INTRODUÇÃO
Small bowel capsule endoscopy (SBCE) has assumed a central role in the investigation of many diseases affecting the small bowel. It enables a non-invasive evaluation of the entire length of the small bowel, providing the highest diagnostic yield among all of currently available non-invasive diagnostic modalities.1 The European Society of Gastrointestinal Endoscopy (ESGE) has recently endorsed a comprehensive guide for the clinical application of enteroscopy.2 The main indications for SBCE are obscure gastrointestinal bleeding (OGIB) and suspected or known Crohn’s disease (CD), followed by other less frequent clinical indications such as suspected small bowel tumors, surveillance of polyposis syndromes and coeliac disease.

3. Life and Health Sciences Research Institute/3B’s. PT Government Associate Laboratory. Braga/Guimarães. Portugal.

Revista Científica da Ordem dos Médicos 632 www.actamedicaportuguesa.com
MATERIAL AND METHODS

This review article was based on a critical analysis of the most relevant and/or recent papers indexed in the PubMed regarding clinical applications of SBCE.

RESULTS AND DISCUSSION

Obscure gastrointestinal bleeding

Obscure gastrointestinal bleeding (OGIB) is defined as bleeding from the gastrointestinal tract that remains undiagnosed after esophagogastroduodenoscopy (EGD) and colonoscopy, generally corresponding to mid-gastrointestinal bleeding, i.e., the origin of bleeding being located in the small bowel between the ampulla of Vater and the ileocecal valve. Clinically, OGIB may present in the form of occult (positive fecal occult blood test and/or iron-deficiency anemia) or overt bleeding (passage of visible blood, usually as melena or hematochezia). It accounts for approximately 5% of all gastrointestinal haemorrhage and up to 30% of all cases of iron-deficiency anemia, although in up to 25% of the cases, the origin of bleeding may in fact be related to missed or recently healed lesions within the reach of EGD or colonoscopy. A systematic review including over 20,000 patients reported OGIB as the most common indication for SBCE, accounting for almost two thirds of cases. In that large review, the most common lesions responsible for bleeding were angioectasias (Fig. 1), accounting for approximately half of the cases, while ulcers and inflammatory lesions, often related to nonsteroidal anti-inflammatory drugs (NSAIDs) or Crohn’s disease, accounted for 26.8% of cases, 8.8% of patients had small bowel neoplastic lesions and 7.7% had other less common type of lesions responsible for the OGIB.

Diagnostic yield of SBCE

In a meta-analysis by Triester et al, the diagnostic yield of SBCE was superior to push enteroscopy [incremental yield (IY) = 30%, small bowel follow-through (IY = 36%), CT enteroclysis (IY = 38%) and MRI (IY = 36%) in patients with OGIB. Marmo et al reported an absolute pooled difference in the rate of positive findings of SBCE versus alternative modalities of 41% (95% CI: 35.6% - 45.9%). The diagnostic yield of SBCE is similar to double-balloon enteroscopy (DBE) providing that both oral and anal insertion route are performed. In routine clinical practice, SBCE is usually the initial test because of its non-invasiveness, ability to view the entire small bowel, and guidance of the initial route of balloon-assisted enteroscopy (BAE), in those cases where patients with positive findings on SBCE will require biopsies or therapeutic intervention. Koulaouzidis et al reported a pooled diagnostic yield of 66.6% (95% CI: 61.0% - 72.3%) in patients with iron-deficiency anemia submitted to SBCE.

Acute overt OGIB

In patients with overt bleeding, the diagnostic yield of SBCE is higher if performed early after its onset. Pennazio et al reported a significantly higher diagnostic yield in patients with ongoing overt OGIB (92.3%) versus occult OGIB (44.2%) or previous history of overt OGIB (12.9%). Bresci et al reported a diagnostic yield of 92% when SBCE was performed within the first two weeks after the diagnosis of OGIB, versus 34% when it was performed later than the second week. Leclerque et al followed a cohort of patients with severe overt OGIB, with negative upper and lower endoscopies performed within 72h after admission, and urgent SBCE performed within the subsequent 48h. Fresh blood was seen in 75% and relevant lesions were detected in 67% of patients, leading to further endoscopic (54%), surgical (22%), or radiological (2%) procedures. In another recent study of 144 patients with overt OGIB, SBCE resulted in higher detection rate of active bleeding and/or angioectasias (44.4% vs 27.8%, p = 0.046) when performed within 72h of hospital admission. In a randomized controlled trial, Leung et al found that the diagnostic yield of SBCE was higher than angiography (53.3% vs 20%; p = 0.016) in patients with severe overt OGIB, and the cumulative risk of rebleeding was 16.7% and 33.3%, respectively (p = 0.10). The use of BAE as the first line examination in this setting has been advocated as a cost-effective approach, due to the high probability of positive findings and the possibility of immediate therapeutic intervention. However, SBCE may still prove useful in those cases, by indicating the optimal route of insertion and by diagnosing possible synchronous lesions.

Rebleeding

Patients with multiple small bowel angioectasias seem to be at the highest risk of bleeding during the follow-up after SBCE. Some authors reported a significant decrease in the risk of rebleeding after SBCE-guided therapeutic interventions. In a recent prospective multicenter study, the rate of rebleeding at twelve months among patients with small bowel vascular lesions detected by SBCE and

Figure 1 – Small bowel angioectasia in a patient with iron-deficiency anemia
subsequently treated with DBE was 35%; multivariate analysis indicated that cardiac disease (HR 2.04, 95% CI: 1.20 - 3.48; p < 0.01) and the presence of overt bleeding (HR 1.78, 95% CI: 1.07 - 2.97; p = 0.03) were independently associated with the risk of rebleding. The negative predictive value of a ‘negative’ SBCE in patients with OGIB is currently debatable. Lai et al. reported a long term rebleding rate of 5.6% in patients with OGIB and ‘negative’ SBCE, versus 48.4% in patients with ‘positive’ findings, p = 0.003. Similarly, Macdonald et al. described that a ‘negative’ SBCE predicts low rebleding rates (11% versus 42%, p < 0.05). Interestingly, in this study none of the patients with ‘occult’ OGIB and ‘negative’ SBCE experienced rebleding. However, other authors have reported higher rates of up to 25% of patients with OGIB and negative SBCE experiencing rebleding. The vast majority within the first two years of follow-up. The overall miss rate for SBCE has been estimated at 10% - 30%, and solitary lesions are more likely to be missed. These different outcomes may reflect distinct inclusion criteria, baseline clinical characteristics or duration of follow-up, as well as differences in inclusion criteria, particularly the case of P1 lesions, such as small erosions or red spots, which have uncertain bleeding potential according to the classification of Saurin et al, while P2 lesions (angioectasias, ulcers, tumors or varices) have a well recognized bleeding risk. Imagawa et al demonstrated improved visibility and detectability of small bowel lesions when using flexible spectral imaging color enhancement (FICE); hence, it could be a reasonable approach to review all ‘negative’ SBCE using the FICE mode before proceeding to further diagnostic investigations.

Small bowel tumors and polyposis syndromes

The most common clinical presentation of small bowel tumors is obscure GI bleeding (OGIB). The prevalence of small bowel tumors in patients with OGIB has been reported to range between 5% and 10%, malignant tumors accounting for 60% to 75% of cases. In a large multicenter study, the main primary small bowel tumor type was gastrointestinal stromal tumor (GIST) (32%), followed by adenocarcinoma (20%) and carcinoid tumor (15%) (Fig. 2); two thirds of metastatic tumors in the small bowel corresponded to melanomas. Up to 70% of the tumors detected by SBCE have been missed by previous imaging studies, particularly when smaller than 10 mm. However, SBCE also has limitations and even large, protruding masses can be overlooked or seen only tangentially on one limited frame of the video. Moreover, SBCE is often unable to distinguish benign from malignant tumors, or even neoplastic from non-neoplastic lesions. In a pooled analysis of 24 prospective studies (n = 530 patients), the failure rate of SBCE in detecting small bowel tumors was reported at 18.9%. SBCE can miss single mass lesions because of limited field of vision, poor bowel preparation, rapid transit especially in the proximal small bowel (duodenum and proximal jejunum), folds and loop angulations hiding masses, lack of insufflation, non-

Differentiating a submucosal tumoral lesion from an innocent bulge on SBCE

Up to half of small bowel malignancies found by SBCE correspond to GIST or neuroendocrine tumors, endoscopically appearing as smooth, round, protruding lesions. Those lesions may be difficult to distinguish from innocent bulges that result from bowel angulation or the impression of an adjacent loop, particularly if some features suggestive of tumoral lesions are absent, such as bleeding, ulceration or irregular surface. The prevalence of smooth, round protrusions at SBCE has been estimated...
at 5.8%, but only approximately 25% of those correspond to submucosal tumors. The Smooth Protruding Index on Capsule Endoscopy (SPICE score) may be helpful to discriminate a bulge from a true mass on SBCE.

**Polyposis syndromes**

The recently released guidelines of the American College of Gastroenterology (ACG) have thoroughly reviewed on the genetic testing and management of hereditary gastrointestinal cancer syndromes. Peutz-Jeghers syndrome (PJS) is characterized by the development of benign hamartomatous polyps in the gastrointestinal tract, especially the small bowel, in association with mucocutaneous pigmentation. Small bowel polyps are prone to complications such as acute gastrointestinal bleeding, intussusception or bowel obstruction, and also have a malignant potential. Small bowel surveillance allows for the detection of large polyps and further referral for endoscopic or surgical removal. The recent ACG guidelines suggest to start with SBCE at age 8 years; if polyps are present, repeat every 3 years; if no polyps are detected, SBCE should be repeated at age 18, then every 3 years, or earlier if symptoms occur. However, it is recognized that even large polyps may be missed by SBCE, especially if located in the proximal small bowel. Gupta et al followed a cohort of 19 patients with 41 polyps greater than 10 mm, which were detected by either MRE or SBCE. Although SBCE was better for the identification of smaller polyps (6-10 mm), it missed three large polyps (>15 mm) that were detected by MRE. Thus, these examinations may be considered complementary. In patients with familial adenomatous polyposis (FAP), there is no evidence to support the routine use of SBCE when the diagnosis is established, as standard endoscopy is superior for the detection of periampullary and duodenal polyps. There is also no current indication for the routine use of SBCE in patients with a diagnosis of Lynch syndrome. In a recent study of 200 asymptomatic patients with Lynch syndrome, the prevalence of small bowel neoplasia was 1.5%, and all neoplastic lesions were located in the duodenum, easily accessible to conventional EGD. The risk of capsule retention may be increased in some patients with polyposis syndromes, such as FAP patients with intra-abdominal desmoid tumors or patients with PJS who underwent previous small bowel surgical resections; therefore, small bowel cross-sectional imaging and/or patency capsule should be performed if SBCE is being considered.

**Crohn’s disease**

**Suspected Crohn’s disease.** Ileocolonoscopy remains the first line examination in patients with suspected Crohn’s disease (CD). However, SBCE may be considered, in the absence of obstructive symptoms or known stenosis, when ileocolonoscopy is non-diagnostic, when retrograde ileoscopy is not technically feasible, or when small bowel lesions proximal to the level reached by the colonoscope are suspected. In patients with suspected small bowel stenoses, SBCE should only be considered if functional patency of the small bowel is previously confirmed by small bowel cross-sectional imaging and/or the Agile™ patency capsule. SBCE has a high sensitivity for lesions consistent with small bowel CD, including mild lesions and those located in the proximal small bowel. In patients with suspected CD, it is possible to confidently exclude the diagnosis when no lesions are identified by SBCE. However, the lesions which are typical of active small bowel CD, such as villous oedema or aphthous ulcerations (Fig. 3), are not disease-specific, looking similar to other entities such as NSAIDs enteropathy, tuberculosis, Behçet's disease, ulcerative jejuno-ileitis, lymphoma, small bowel ischemia or radiation enteropathy. There are no validated diagnostic criteria for establishing the diagnosis of CD by SBCE. The Lewis Score (LS) and the Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI) have been validated as cumulative quantitative scores that measure the severity of inflammatory activity, and contribute to standardise reporting and increase interobserver agreement. A software application for the automatic calculation of the LS is available in the Rapid Reader workstation (Given Imaging, Yokneam, Israel).

![Figure 3](image.png)
chronic abdominal pain, chronic diarrhoea, weight loss or growth failure, ‘in addition’ to extra-intestinal manifestations typical of IBD such as fever, arthritis/arthralgia, pyoderma gangrenosum, perianal disease and/or primary sclerosing cholangitis, raised serum and/or inflammatory markers, and/or abnormal small bowel imaging. In a retrospective study, SBCE detected significant inflammatory activity in 17.8% of patients who did not meet those ICCE criteria, in 57.9% of those fulfilling two criteria and in 77.8% when 3 or more criteria were present, and CD was confirmed during follow-up in 21.4%, 52.6% and 77.8% of these patients, respectively.50 SBCE may also be useful in patients with inflammatory bowel disease unclassified (IBDU), although a negative examination cannot definitely exclude a future diagnosis of CD51 in this setting.


In patients with known CD, irrespective of the findings at ileocolonoscopy, the small bowel should be investigated to evaluate disease extent and activity,52 as it may influence prognosis and therapeutic decisions. Cross sectional imaging with CTE or MRE generally takes precedence over SBCE, being able to identify strictures and to assess the transmural and extra-luminal nature of the disease and its anatomical distribution. In the absence of clinical or radiological evidence of stenoses, SBCE may be considered if additional findings are likely to result in a modification of clinical management.53 Although the risk of capsule retention is slightly increased in these patients, it can often be managed conservatively or retrieved by BAE.54 SBCE improves the detection of lesions in the proximal small bowel when compared to both CTE and MRE, detecting proximal lesions in up to 50% of patients with previously diagnosed ileal CD.55 Jejunal involvement has been recognized as an independent marker of severity in CD, being associated with an increased risk of relapse,56 higher use of corticosteroids (HR 1.24; 95% CI: 1.02 - 1.50) and thiopurines (HR 1.26; 95% CI: 1.06 - 1.49), higher rates of strictureplasties (RR 2.52; 95% CI: 1.60 - 3.96), hospitalizations (RR 1.29; 95% CI: 1.14 - 1.47), and longer hospitalization duration (RR, 1.30; 95% CI, 1.25 - 1.34).56 Recently, it was reported that treatment with thiopurines and/or biologics was started more often in patients with proximal small bowel lesions detected by SBCE [13/33 (39%) vs 1/17 (6%), p = 0.011, relative risk (RR) 6.5], particularly when severe (6%, 36% and 45% of patients with non-significant, mild and moderate-to-severe inflammation, respectively).53

Patients with suspected obscure GI bleeding or ongoing symptoms.

SBCE has been used to investigate CD patients in the setting of unexplained iron-deficiency anaemia or visible OGIB,41 or to investigate patients with ongoing symptoms suggestive of active disease.57 Mehdizadeh et al58 reported normal SBCE findings in 48% of symptomatic patients with small bowel CD, guiding the investigation to alternative diagnoses such as concurrent irritable bowel syndrome, bile salt malabsorption or bacterial overgrowth.

Assessment of mucosal healing

Small bowel mucosal healing is an important endpoint of treatment efficacy. The use of validated quantitative scales with good inter-observer agreement such as the Lewis score59 or the CECDAI,47 with adoption of a standardized definition of mucosal healing, seems particularly relevant in this setting. SBCE enables a longitudinal assessment of the course of the disease and its response to medical therapy.50,61 However, there is currently insufficient evidence to support its use for this indication in routine clinical practice.

Postoperative disease recurrence

Pons Beltran et al62 evaluated 24 CD patients for postoperative recurrence. SBCE detected CD neo-terminal ileal disease recurrence in 62% of patients, whereas ileocolonoscopy detected inflammatory lesions within the neo-terminal ileum in 25% of patients. Conversely, in another study, the sensitivity of SBCE for endoscopic recurrence in the neo-terminal ileum was inferior to that of ileocolonoscopy, although proximal lesions were detected in more than two thirds of patients.63 Although SBCE has been shown to detect proximal small bowel lesions in patients with CD early after surgery, the clinical significance of these findings and how they may impact on patient management is currently unknown. Thus, SBCE should currently be considered only when ileocolonoscopy is unsuccessful for the assessment of postoperative recurrence.

Celiac disease

Celiac disease is one of the most prevalent enteropathies in western countries, affecting 0.2 - 2% of the population.64 The first step for diagnosing celiac disease is usually a serological test, using the immunoglobulin A (IgA) anti-human tissue transglutaminase (t-TG) and IgA endomysial antibody immunofluorescence (EMA). Although serological testing is highly sensitive and specific, EGD with biopsies of the duodenum remains the standard for the diagnosis of celiac disease. Four typical endoscopic markers of celiac disease have been described: loss or reduction in duodenal Kerkring’s folds, mosaic or micronodular mucosal pattern, scalloped configuration of duodenal folds and visibility of the underlying blood vessels.65 The reported specificity for these classical endoscopic markers ranges from 87% to 100%, while the sensitivity may range from 50% to 94%.66,67 Therefore, small bowel histopathology remains essential for the diagnosis, typically showing villous atrophy, increased intraepithelial lymphocytes and hyperplastic crypts.65 However, adequate and properly oriented tissue samples are sometimes difficult to obtain, and patchy mucosal lesions may be missed, precluding a definite histopathologic diagnosis. A few studies have reported a sensitivity of 67% - 93%, specificity of 63.6% - 100%, positive predictive value (PPV) of 96.5% - 100% and negative predictive value...
be observed in more than half of patients with refractory bowel damage. Poor nutritional status and low serum albumin levels have also been associated with extensive small disease. In patients with an established diagnosis of celiac disease, SBCE has the main advantage of being a non-invasive technique capable of visualizing the entire small bowel, establishing the extent of small bowel involvement and enabling the diagnosis of complications of long-standing celiac disease, such as small bowel adenocarcinoma, enteropathy associated T-cell lymphoma (EATL) and ulcerative jejuno-ileitis, which are often located beyond the site reached by EGD, and may also be missed by other small bowel imaging modalities. Petroniene et al reported that the extent of small bowel involvement may be related to the severity of symptoms in celiac disease. Poor nutritional status and low serum albumin levels have also been associated with extensive small bowel damage. Extensive ulcerative jejuno-ileitis may be observed in more than half of patients with refractory celiac disease (RCD) type II (54%) and it is associated with a high risk of developing EATL. The risk of capsule retention in patients with suspected complications of long-standing celiac disease advises preliminary radiological imaging of the small bowel or patency capsule in order to rule out strictureing disease. In a series of 47 high risk celiac patients with persistent unexplained abdominal pain, weight loss, history of small bowel neoplasia, long-standing celiac disease, positive faecal occult blood test or iron deficiency anaemia unresponsive to iron supplementation, SBCE detected significant lesions in approximately 60% of cases. These data support the use of SBCE in patients with long-standing complicated celiac disease, who present with alarm symptoms or do not respond to gluten-free diet.

CONCLUSIONS
SBCE revolutionized the diagnostic approach of small bowel diseases, and its relative positioning within the management algorithms of patients with OGB, suspected small bowel tumors, CD and coeliac disease has been rapidly evolving in the past few years. In the future, new features such as the ability to obtain new image reconstructions, sample luminal fluids and mucosal tissue or the possibility to remotely control the capsule and performing therapeutic procedures are likely to further expand the field of capsule technology, providing new high-tech management opportunities with the compromise of less invasiveness and convenience for patients.

CONFLICTS OF INTEREST
The authors state no conflict of interests and have received no payment to perform this work.

FUNDING SOURCES
No subsidies or grants contributed to this work.

REFERENCES
16. Hindryckx P, Botelenge B, De Vos M, De Looze D. Clinical impact of


Bruno ROSA, José COTTER

Current Clinical Indications for Small Bowel Capsule Endoscopy


Publicado pela Acta Médica Portuguesa, a Revista Científica da Ordem dos Médicos

Av. Almirante Gago Coutinho, 151
1749-084 Lisboa, Portugal.
Tel: +351 218 428 215
E-mail: submissao@actamedicaportuguesa.com
www.actamedicaportuguesa.com
ISSN:0870-399X | e-ISSN: 1646-0758